Total Funding
83
58
Total FundingSeed raised
Growth Score
-9 pts
Heat Score
-24 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
42867
Mavatar – AI, Digital Twins, and the End of Mismedication
- Ulrika Nyberg: Head of Strategic Partnerships
- Johan Juhlin: CEO and Co-founderPast Role: Beckman Coulter, Managing Director Nordic
About the Company
Mavatar is revolutionizing precision medicine with proprietary AI technologies, drawing on over 20 years of research to transform personalized healthcare. Our cutting-edge solutions accelerate pharmaceutical development by identifying novel therapeutic targets through genomic analysis and enable highly individualized treatments with digital patient
replicas. By leveraging advanced AI and big data, Mavatar is reshaping how diseases are understood and treated, driving lasting progress in global healthcare.
